Connect your AI

NewAmsterdam Pharma Company NAMS Price / book

Price / book at other companies

Merck & Co.MRK

6.5×+1.8×

AmgenAMGN

20.6×-6.3×

Regeneron PharmaceuticalsREGN

2.6×+0.2×

Eli LillyLLY

26.3×-20.7×

Denali Therapeutics Inc.DNLI

3.3×+1.5×

Other financials

Income statement

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

Market cap$3.67B+63.7%

Profitability

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Calculated from NewAmsterdam Pharma Company’s reported figures.

market cap/total stockholders equity=5.5×

Based on the most recent quarter.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is NewAmsterdam Pharma Company's price / book?: NewAmsterdam Pharma Company (NAMS) reported price / book of 5.5× in Q1 2026.
How has NewAmsterdam Pharma Company's price / book changed year-over-year?: NewAmsterdam Pharma Company's price / book increased by 91.3% year-over-year, from 2.9× to 5.5×.
What is the long-term trend for NewAmsterdam Pharma Company's price / book?: Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's price / book has grown at a 36.7% compound annual growth rate (CAGR), from 2.3× to 5.8×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.